Overall Status

Active, not recruiting (1)

Recruiting (1)

Terminated (1)

Phase

phase 2 (2)

phase 1/phase 2 (1)

Sponsor

Mayo Clinic (2)

Acerta Pharma BV (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

acalabrutinib (2)

durvalumab (1)

ibrutinib (1)

idelalisib (1)

laboratory biomarker analysis (1)

pembrolizumab (1)

venetoclax (1)

vistusertib (1)

Study Documents

Intervention Type

drug (3)

biological (2)

other (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

Richter Syndrome

Showing NaN - NaN of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting

Chronic Lymphocytic Leukemia
+2 more

Acalabrutinib
+2 more

Rochester, Minnesota

Mayo Clinic in Rochester

Jan 4, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting

Recurrent B-Cell Non-Hodgkin Lymphoma
+22 more

Ibrutinib
+3 more

Scottsdale, Arizona
+1 more

Aug 10, 2021

DLBCL, Richter Syndrome Trial in United Kingdom, United States (acalabrutinib, vistusertib)

Terminated

Has Results

DLBCL
Richter Syndrome

Fairway, Kansas
+10 more

Jan 4, 2021